Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22002858 | 0.79 | GRIA1 (0.34) | GRIA1 | |
| SCHEMBL8360658 | 0.74 | GRIA1 (0.39) | GRIA1 | |
| SCHEMBL26144750 | 0.70 | GRIA1 (0.37) | GRIA1 | |
| SCHEMBL23872667 | 0.70 | GRIA1 (0.36) | GRIA1 | |
| SCHEMBL12386315 | 0.69 | CA1 (0.40) | GRIA1 | |
| SCHEMBL18609172 | 0.67 | — | — | |
| SCHEMBL18595757 | 0.67 | GRIA1 (0.38) | GRIA1 | |
| SCHEMBL26144753 | 0.67 | GRIA1 (0.33) | GRIA1 | |
| SCHEMBL24846538 | 0.67 | GRIA1 (0.33) | GRIA1 | |
| SCHEMBL22002925 | 0.67 | GRIA1 (0.48) | GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338311-A1 | SUPPRESSION OF INFLAMMASOME ACTIVATION | WASHINGTON UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20220242812-A1 | SWELL1-LRRC8 COMPLEX MODULATORS | WASHINGTON UNIVERSITY (US) | 2022-08-04 | — | — | US | disclosed |
| US-10654833-B2 | ASK1 isoindolin-1-one inhibitors and methods of use thereof | HEPATIKOS THERAPEUTICS, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200039989-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GRIA1 1272/4885 |
| US-10654833-B2 | ASK1 isoindolin-1-one inhibitors and methods of use thereof | ATF1, MAP3K20, MAP3K1 | GRIA1 1911/4885 |
| US-20200039989-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | GRIA1 1288/4885 |
| US-20230338311-A1 | SUPPRESSION OF INFLAMMASOME ACTIVATION | NLRP3, IL1B, NOD2 | GRIA1 1258/4885 |
| US-20220242812-A1 | SWELL1-LRRC8 COMPLEX MODULATORS | LRRC47, LRRC59, LRRFIP1 | GRIA1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.